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ABSTRACT
Background In models of COPD, environmental
stressors induce innate immune responses, inﬂammasome
activation and inﬂammation. However, the interaction
between these responses and their role in driving
pulmonary inﬂammation in stable COPD is unknown.
Objectives To investigate the activation of innate
immunity and inﬂammasome pathways in the bronchial
mucosa and bronchoalveolar lavage (BAL) of patients
with stable COPD of different severity and control healthy
smokers and non-smokers.
Methods Innate immune mediators (interleukin (IL)-6,
IL-7, IL-10, IL-27, IL-37, thymic stromal lymphopoietin
(TSLP), interferon γ and their receptors, STAT1 and
pSTAT1) and inﬂammasome components (NLRP3, NALP7,
caspase 1, IL-1β and its receptors, IL-18, IL-33, ST2) were
measured in the bronchial mucosa using
immunohistochemistry. IL-6, soluble IL-6R, sgp130, IL-7,
IL-27, HMGB1, IL-33, IL-37 and soluble ST2 were
measured in BAL using ELISA.
Results In bronchial biopsies IL-27+ and pSTAT1+ cells
are increased in patients with severe COPD compared
with control healthy smokers. IL-7+ cells are increased in
patients with COPD and control smokers compared with
control non-smokers. In severe stable COPD IL-7R+,
IL-27R+ and TSLPR+ cells are increased in comparison
with both control groups. The NALP3 inﬂammasome is
not activated in patients with stable COPD compared with
control subjects. The inﬂammasome inhibitory molecules
NALP7 and IL-37 are increased in patients with COPD
compared with control smokers. IL-6 levels are increased
in BAL from patients with stable COPD compared with
control smokers with normal lung function whereas IL-1β
and IL-18 were similar across all groups.
Conclusions Increased expression of IL-27, IL-37 and
NALP7 in the bronchial mucosa may be involved in
progression of stable COPD.
INTRODUCTION
Inﬂammation is important in the pathogenesis of
stable COPD.1 Environmental stress such as cigar-
ette smoke activates the innate immune response
which may drive COPD inﬂammation.2 Interleukin
6 (IL-6) is a multifunctional pro-inﬂammatory cyto-
kine1 that acts via two molecules: the IL-6R (IL-6
receptor) and gp130.3 Soluble gp130 (sgp130) inhi-
bits IL-6 trans-signalling via the soluble IL-6R
(sIL-6R) and classic signalling via the membrane
bound IL-6R (mIL-6R).4
IL-27, an IL-12/IL-23 family member, stimulates
T helper 1 (Th1) lymphocyte differentiation.5 It
also stimulates haematopoiesis, increases antigen
presentation by antigen-presenting cells and inhibits
angiogenesis.6 The IL-27 receptor (IL-27Ra or
WSX-1) activates the Janus kinase ( JAK) pathway
with phosphorylation of signal transducer and acti-
vator of transcription (STAT)-1 and STAT3.6 IL-10,
in contrast, potently inhibits the expression of
inﬂammatory proteins such as IL-1β, tumour necro-
sis factor α and matrix metalloproteinase 9.1
IL-7 is primarily produced by stromal and epithe-
lial cells7 8 and promotes human T-cell development,
naïve T-cell homeostasis, T-cell proliferation and sur-
vival of memory T cells.7 8 IL-7 binds to the IL-7R, a
heterodimer consisting of the IL-7Rα (CD127) and
the common γ chain (γc or CD132), causing STAT1
and STAT3 activation.7 Thymic stromal lymphopoie-
tin (TSLP) is an IL-7 family member involved in the
activation, expansion and survival of T lymphocytes
and dendritic cells acting through a heterodimeric
IL-7Rα and TSLPR complex.9
High mobility group box 1 (HMGB1) is a
nuclear protein that can act as a damage-associated
Key massages
What is the key question?
▸ Are innate immunity and/or inﬂammasome
activation in the upper and lower airways
involved in the progression of severity of stable
COPD?
What is the bottom line?
▸ In our study the increased expression of the
innate immunity inﬂammatory mediators
interleukin (IL)-6, IL-27, IL-37 and NALP7 in the
bronchial mucosa and/or bronchoalveolar
lavage may be involved in the progression of
the severity of stable COPD.
Why read on?
▸ The lack of evidence for inﬂammasome
activation in the upper and lower airways of
patients with stable COPD suggests that this
inﬂammatory pathway is not involved in the
progression of the severity of stable COPD.
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molecular pattern to activate immune cells, including Th1
lymphocytes.10
NLRs are categorised into ﬁve subfamilies.11 12 A typical
inﬂammasome is composed of an NLR, an adaptor protein such
as apoptosis-associated speck-like protein containing a CARD
(ASC) and an effector caspase that activates proinﬂammatory
cytokines. Within the NRLP3 complex, auto-catalytic cleavage
of pro-caspase 1 enables removal of IL-1β and IL-18 pro
sequences resulting in biologically active forms and thereby initi-
ating Th1 and Th17 adaptive immune responses.11 13 HMGB1
is also induced by NRLP3 activation.11 12 The expression of
IL-33, another member of the IL-1 family, may also be enhanced
through activation of the inﬂammasome.14 IL-33 acts through
its receptor ST2 and may activate immune cells.15 IL-6 is
induced by NRLP3 but in an inﬂammasome-independent
manner.16
The NLRP3 inﬂammasome is activated by infectious agents,
double-strand DNA and extracellular ATP.2 11 NALP7 decreases
transcription of pro-IL-1β expression and IL-10 and IL-27 can
modulate NRLP3 activity2 whereas IL-37 can downregulate
inﬂammation and innate immunity independently of the inﬂam-
masome.17 18
The aim of this study was to investigate the presence of
innate immune mediators (IL-6, IL-7, IL-10, IL-27, IL-37, TSLP,
interferon γ (IFNγ), their receptors, and signalling proteins
STAT1 and pSTAT1) and inﬂammasome components (NLRP3,
caspase 1, IL-1β, IL-18, IL-33, NALP7, ST2) in the bronchial
mucosa and bronchoalveolar lavage (BAL) of patients with
stable COPD of differing severity and age-matched control sub-
jects with normal lung function.
METHODS
Subjects
All subjects were recruited from the Respiratory Medicine Unit
of the ‘Fondazione Salvatore Maugeri’ (Veruno, Italy), the
Section of Respiratory Diseases of the University Hospital of
Ferrara, Italy and the Section of Respiratory Diseases of the
University Hospital of Katowice, Poland for immunohistochemis-
try and ELISA experiments. The severity of the airﬂow limitation,
as determined by spirometry, was graded using Global Initiative
for Chronic Obstructive Lung Disease (GOLD) criteria.19 All
former smokers had stopped smoking for at least 1 year. COPD
and chronic bronchitis were deﬁned, according to international
guidelines: COPD, presence of a post-bronchodilator forced
expiratory volume in 1s (FEV1)/forced vital capacity ratio <70%;
chronic bronchitis, presence of cough and sputum production
for at least 3 months in each of two consecutive years (http://
www.goldcopd.com). All patients with COPD were stable. The
study conformed to the Declaration of Helsinki. We obtained
and studied bronchial biopsies from 55 subjects: 32 had a diagno-
sis of COPD in a stable clinical state,20 12 were current or
ex-smokers with normal lung function, and 11 were non-smokers
with normal lung function (table 1). The smoking history was
similar in the three smoker groups: mild/moderate and severe/
very severe COPD, and healthy smokers with normal lung func-
tion. Clinical details of the patients in whom BAL was collected
are summarised in table 2. The results provided are the data from
26 patients with COPD and 18 control smokers with normal
lung function. Due to the necessity to concentrate the BAL super-
natants the results provided for each ELISA are the data from 15
patients with COPD and 14 control smokers with normal lung
function which are not the same patients for all mediators
measured.
A detailed description of subjects, lung function tests, ﬁbreop-
tic bronchoscopy and processing of bronchial biopsies and BAL,
immunohistochemistry, scoring system for immunohistochemis-
try, double staining and confocal microscopy, ELISA tests per-
formed on the BAL ﬂuid and ‘in vitro’ experiments performed
on normal human bronchial epithelial (NHBE) cells and details
of statistical analysis are provided in the online supplementary
data repository.
Statistical analysis
Differences between groups were analysed using analysis of vari-
ance and Kruskal–Wallis tests. Correlation coefﬁcients were cal-
culated using the Spearman rank method.
RESULTS
Measurement of inﬂammatory cells in the bronchial
submucosa
These results are reported in full in the online supplementary
data repository and in table E1. Brieﬂy, these data conﬁrm
Table 1 Clinical characteristics of subjects studied by immunohistochemistry
Control
non-smokers
Control smokers
normal lung function
COPD grade I/II
(mild/moderate)
COPD grade III/IV
(severe/very severe)
Number 11 12 14 18
Age (years) 67±1 61±7 67±8 66±9
M/F 10/1 9/3 12/2 11/7
Pack years 0 43±26 40±19 54±36
Ex/current smokers 0 2/10 5/9 13/5
FEV1 pre-β2 (% predicted) 116±14 104±13 66±14* 35±8*
,**
FEV1 post-β2 (% predicted) ND ND 72±12 38±9
FEV1/FVC (%) 85±10 81±6 60±8* 44±10*
,**
Chronic bronchitis 0 5 8 6
Patients were classified according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) (http://www-goldcopd.org) grades of severity for COPD into mild (stage I), moderate
(stage II), severe (stage III) and very severe (stage IV).
Patients with COPD were using short-acting inhaled β2 agonists (SABAs) or short-acting inhaled antimuscarinics (SAMAs) as needed or regular long-acting inhaled β2 agonists (LABAs)
and/or regular inhaled anticholinergics, including SAMA or long-acting inhaled antimuscarinics at the dosage recommended in current COPD guidelines (http://www.goldcopd.org) at the
time of their recruitment.
Data expressed as means±SEM. For patients with COPD FEV1/FVC (%) are post-bronchodilator values.
Statistics (ANOVA): *p<0.0001, significantly different from control smokers with normal lung function and control never smokers; **p<0.0001, significantly different from patients with
mild/moderate COPD.
F, female, FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; M, male; ND, not determined.
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elevated numbers of CD8 T cells, CD68 macrophages and neu-
trophils in patients with COPD.20
Immunohistochemistry for innate immunity and
inﬂammasome pathways in the bronchial epithelium
The number of IL-27+ (ﬁgure 1 and table 3), IL-27R+, TSLPR+,
NALP7 and STAT1 immunoreactive cells was increased in the epi-
thelium of patients with severe stable COPD compared with
control non-smokers (p=0.0048, p=0.017, p=0.008, p=0.054,
p=0.011, respectively). IL-27+, TSLPR+, NALP7+ and STAT1+
cells also differed signiﬁcantly in comparison with control healthy
smokers (p=0.043, p=0.0019, p=0.0009 and p=0.023, respect-
ively) (table 3). In contrast, no signiﬁcant differences in bronchial
epithelial expression of IL-1β, IL-1βRI and RII, caspase-1, IL-18,
IL-18Rα, IL-18Rβ, IL-18BP, NLRP3, IL-6, IL-6Rα, IL-7, IL-7Rα,
IL-10, IL-10Rα, IL-33, ST-2, IFNγ, IFNγRI, pSTAT1, TSLP
and IL-37 were observed between groups (table 3). Due to the
fewer number of subjects who were current smokers within the
severe stable COPD group we were unable to perform subanalysis
of current versus former smokers across groups.
Immunohistochemistry for innate immunity and
inﬂammasome pathways in the bronchial submucosa
Mononuclear cells (lymphocytes and macrophages) and endo-
thelial cells were the most represented immunostained cells in
the submucosa. The number of IFNγ+ cells was signiﬁcantly
higher in patients with mild/moderate (p=0.010) and severe
(p=0.008) stable COPD compared with control non-smokers,
conﬁrming previously reported data.21 The number of
IFNγRI+ cells was increased in patients with severe COPD
compared with patients with mild COPD (p=0.031), control
smokers (p=0.0035) and control non-smokers (p=0.006).
IL-18Rβ showed a slight increase in patients with severe COPD
compared with those with mild/moderate COPD (p=0.045)
and control smokers (p=0.039) but did not differ in compari-
son with control non-smokers. The number of IL-7+ (see
online supplementary ﬁgure E1) cells was higher in patients
with severe COPD (p=0.008), patients with mild/moderate
COPD (p=0.010) and in control smokers (p=0.012) compared
with control non-smokers. In addition, the number of IL-7Rα+
Figure 1 Photomicrographs showing the bronchial mucosa from (A) control non-smoker, (B) control healthy smoker with normal lung function,
(C) patient with mild/moderate stable COPD and (D) patient with severe stable COPD immunostained for identiﬁcation of IL-27+ cells (arrows) in the
epithelium and bronchial submucosa. Results are representative of those from 11 non-smokers, 12 healthy smokers, 14 patients with mild/moderate
COPD and 18 patients with severe COPD. Bar=30 μm.
Table 2 Clinical characteristics of the subjects for the BAL study
Smokers with
normal lung function
Patients with
mild to moderate
stable COPD
Number 18 26
Age 64.4±2.0 67.9±1.6
Sex (M/F) 15/3 19/F
Ex/current smokers 10/8 12/14
Pack-years 37.8±3.0 39.6±5.5
Chronic bronchitis 10 14
FEV1 % predicted 88.2±4.9 57.9±3.0
FEV1/FVC % 79.2±1.8 56.8±2.5
FEV1 % predicted and FEV1/FVC % are post-bronchodilator values. Patients with
COPD were using short-acting inhaled β2 agonists or short-acting inhaled
antimuscarinics (SAMAs) as required or regular long-acting inhaled β2 agonists and/or
regular inhaled anticholinergics, including SAMAs or long-acting inhaled
antimuscarinics at the dosage recommended in current COPD guidelines (http://www.
goldcopd.org) at the time of their recruitment. Data expressed as means±SEM.
BAL, bronchoalveolar lavage; F, female; FEV1, forced expiratory volume in 1s;
FVC, forced vital capacity; M, male.
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Table 3 Immunohistochemical quantification of innate immunity and inflammasome pathways expression in the bronchial mucosa
Healthy non-smokers Healthy smokers Patients with mild/moderate COPD Patients with severe COPD p Value
Epithelium (score 0–3)
IL-6 0.25 (0–0.5) 0.25 (0–0.5) 0.25 (0–1) 0.25 (0–1) 0.346
IL-6 Rα 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) n.v.
IL-7 0.5 (0.5–1) 0.75 (0.25–2) 0.5 (0.25–1.5) 0.75 (0.5–2) 0.671
IL-7 Rα 0 (0–0) 0 (0–0) 0 (0–0.5) 0 (0–0.5) 0.985
IL-10 0 (0–0.25) 0 (0–0.25) 0 (0–0.5) 0 (0–0.5) 0.513
IL-10 Rα 0 (0–0.25) 0 (0–0.25) 0 (0–0.25) 0 (0–0.25) 0.688
IL-27 0.5 (0.25–1) 0.75 (0.25–1.5) 0.75 (0–1.5) 1 (0.5–2)*,** 0.0279
IL-27 R 0 (0–0.5) 0.25 (0–0.5) 0.25 (0–0.75) 0.25 (0–1)* 0.0748
IL-33 0 (0–0.25) 0 (0–0.25) 0 (0–0.25) 0 (0–0.75) 0.962
ST2 0 (0–0) 0 (0–0) 0 (0–0.25) 0 (0–0.25) 0.752
TSLP 0.25 (0–1) 0.25 (0–1) 0.5 (0–1) 0.37 (0–1) 0.545
TSLP-R 0.25 (0.25–0.5) 0.25 (0.25–0.5) 0.5 (0.25–1.5) 1 (0.25–1.25)*,** 0.007
IL-18 1 (0.5–2) 1 (0.5–2.5) 1.5 (0.25–2.5) 1 (0.5–2.5) 0.386
IL-18 Rα 2.5 (0.75–2.75) 2.5 (1–3) 2.5 (1–3) 2.5 (1–3) 0.869
IL-18 Rβ 2.25 (1–2.5) 1 (0.25–2.5) 1.5 (0–2.5) 2 (1–2.75) 0.095
IL-18 BP 0 (0–0) 0 (0–0.25) 0 (0–0.5) 0 (0.25) 0.093
NLRP-3 1.62 (1–2) 1.5 (1–2.75) 1.5 (1–3) 2 (1.5–2.5)*** 0.220
Caspase-1 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) n.v.
IL-1β 0 (0–0.25) 0 (0–0.25) 0 (0–0.25) 0 (0–0.5) 0.671
IL-1β RI 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) n.v.
IL-1β RII 0 (0–0.25) 0.25 (0–0.5) 0.25 (0–1) 0.25 (0–1) 0.380
IL-37 1.5 (0.25–2.25) 1.5 (0.25–2.25) 1.12 (0.75–2.0) 1.5 (0.75–2.25) 0.915
NALP7 1.25 (0.5–2.5) 0.62 (0.25–1.75) 1.62 (0.25–2.5) 1.87 (0.5–3.0)*,** 0.006
STAT1 0.37 (0.25–1.5) 0.5 (0.0–2.0) 1.0 (0.25–2.25) 1.37 (0.25–2.75)*,** 0.018
pSTAT1 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) n.v.
IFN-γ 0 (0–0.25) 0 (0–0.25) 0 (0–0) 0 (0–0.25) 0.938
IFN-γ RI 1.5 (0.75–2.25) 1.25 (0.75–2.5) 1.25 (0.75–3) 2.25 (0.75–2.5) 0.282
Submucosa (cells/mm2) median (range)
IL-6 24 (9–54) 27.5 (8–64) 36.5 (4–126) 44 (6–169) 0.294
IL-6 Rα 0 (0–22) 11 (0–55) 7 (0–18) 10 (0–37) 0.259
IL-7 72 (32–226) 126 (56–269)* 140 (32–484)* 140 (52–323)* 0.023
IL-7 Rα 13 (0–71) 32 (6–108) 44.5 (5–183) 91 (16–302)*,**,*** 0.0053
IL-10 0 (0–12) 7 (0–28)* 6.5 (0–113)* 9 (0–55)* 0.0519
IL-10 Rα 0 (0–4) 0 (0–8) 0 (0–48) 0 (0–23) 0.367
IL-27 54 (8–113) 51 (14–140) 73 (9–400) 77 (36–542)** 0.113
IL-27 R 12 (0–24) 9 (0–51) 35 (0–81)*,** 48 (6–155)*,** 0.0027
IL-33 5 (0–9) 6 (0–23) 5 (0–54) 6 (0–86) 0.606
ST-2 0 (0–5) 0 (0–8) 0 (0–16) 0 (0–7) 0.722
TSLP 14 (0–29) 11 (0–38) 17 (0–90) 12 (0–81) 0.498
TSLP-R 18 (5–43) 12 (0–86) 55 (0–277)** 49 (7–269)*,** 0.011
IL-18 123 (11–203) 59 (16–355) 170 (16–419) 107 (8–488) 0.381
IL-18 Rα 177 (61–203) 152 (81–242) 231 (71–424) 214 (59–525) 0.118
IL-18 Rβ 138 (90–210) 69 (5–236) 104 (5–232) 182 (48–302)**,*** 0.043
IL-18 BP 5 (0–97) 0 (0–32) 0 (0–18) 0 (0–16) 0.258
NLRP-3 104 (73–183) 111 (41–274) 166 (56–348) 121 (84–403) 0.261
Caspase-1 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) n.v.
IL-1β 0 (0–5) 6 (0–24) 5 (0–56) 4 (0–89) 0.298
IL-1β RI 0 (0–7) 0 (0–7) 0 (0–16) 0 (0–14) 0.362
IL-1β RII 0 (0–11) 0 (0–16) 0 (0–18) 0 (0–26) 0.882
IL-37 145 (43–258) 107 (58–355) 282 (113–441)*,** 213 (64–452)** 0.024
NALP7 167 (29–270) 85 (11–242) 210 (32–462)** 177 (45–456)** 0.005
STAT1 35 (19–102) 22 (13–129) 110 (9–210)*,** 129 (8–274)*,** 0.005
pSTAT1 37 (0–156) 8 (0–127) 41 (0–158) 67 (0–173)** 0.0887
IFN-γ 12 (0–46) 14.5 (0–115) 20 (3–90)* 22 (4–82)* 0.051
IFN-γRI 146 (118–298) 183 (113–460) 226 (129–672) 344 (170–631)*,**,*** 0.0046
Data expressed as median (range). Statistics: the Kruskal–Wallis test was used for multiple comparisons followed by the Mann–Whitney U test for comparison between groups:
*p<0.05, significantly different from control non-smokers; **p<0.05, significantly different from control smokers with normal lung function; ***p<0.05, significantly different from
patients with mild COPD. The exact ‘p’ values for comparison between groups are given in the Results section.
IFN, interferon; IL, interleukin; n.v., no value; TSLP, thymic stromal lymphopoietin.
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cells was signiﬁcantly higher in patients with severe COPD com-
pared with patients with mild/moderate COPD (p=0.040),
control smokers (p=0.009) and control non-smokers
(p=0.002). IL-10 was poorly expressed but the number of
IL-10+ cells was higher in patients with severe stable COPD
(p=0.005), patients with mild/moderate COPD (p=0.047) and
in control smokers (p=0.054) compared with control
non-smokers.
The number of IL-27+ (ﬁgure 1) and pSTAT1+ (see online sup-
plementary ﬁgure E2) cells was signiﬁcantly higher in patients
with severe COPD (p=0.032 and p=0.018, respectively) com-
pared with control smokers but did not differ in comparison with
the other groups. Interestingly, the number of IL-27R+ cells was
signiﬁcantly higher in patients with severe COPD (p=0.010 and
p=0.002) and patients with mild/moderate COPD (p=0.054 and
p=0.009) compared with control smokers and non-smokers.
Similarly, the number of total STAT1+ cells was signiﬁcantly
higher in patients with severe COPD (p=0.0043 and p=0.015)
and patients with mild/moderate COPD (p=0.022 and p=0.029)
compared with control smokers and non-smokers.
The number of TSLPR+ cells was higher in patients with
severe COPD compared with control smokers (p=0.005) and
non-smokers (p=0.044). TSLPR+ cell numbers were also
increased in patients with mild/moderate stable COPD with
control smokers (p=0.013).
The number of IL-37+ (ﬁgure 2) and NALP7+ (see online
supplementary ﬁgure E3) cells was higher in patients with
severe stable COPD compared with control smokers (p=0.054
and p=0.0015 respectively) and in patients with mild/moderate
stable COPD in comparison with control smokers (p=0.008
and p=0.0043 respectively). Furthermore, the number of IL-37
+ cells in patients with mild/moderate stable COPD was signiﬁ-
cantly increased in comparison with control non-smokers
(p=0.023) (table 3).
No signiﬁcant differences were observed for IL-1β, IL-1βRI,
IL-1βRII, caspase-1, IL-18, IL-18Rα, IL-18BP, NLRP3, IL-6,
IL-6Rα, IL-10Rα, IL-33, ST-2 and TSLP immunostaining between
groups.
Double staining and confocal microscopy
The percentage of CD68+IL-27+ double-stained cells was sig-
niﬁcantly increased in patients with COPD (34±8%) compared
with control smokers (8±2%, p=0.0209) (see online supple-
mentary ﬁgure E4 and data repository for more details).
ELISA assays in the BAL supernatants
BAL levels of IL-6 were signiﬁcantly increased in patients with
stable COPD compared with the control healthy smokers
(p=0.0001; ﬁgure 3A), without a signiﬁcant change in the BAL
level of sIL-6R and sgp130 between the two groups (see online
supplementary ﬁgure E5A and E6A). In contrast, BAL IL-7 (see
online supplementary ﬁgure E5B) and IL-27 (see online supple-
mentary ﬁgure E5C) levels were not signiﬁcantly different
between the two subject groups. BAL HMGB1 was signiﬁcantly
decreased in patients with stable COPD compared with control
healthy smokers (p=0.0174; ﬁgure 3C). However, this differ-
ence was lost after removal of the outliers (p=0.0540). The
BAL level of soluble ST2 (p=0.0073; ﬁgure 3D) and IL-1RA
(p=0.0307; ﬁgure 3B) are signiﬁcantly decreased in patients
with stable COPD compared with control smokers with normal
lung function without signiﬁcant changes in the BAL level
of IL-1β (see online supplementary ﬁgure E6B), IL-18 (see
Figure 2 Photomicrographs showing the bronchial mucosa from (A) control non-smoker, (B) control healthy smoker with normal lung function,
(C) patient with mild/moderate stable COPD and (D) patient with severe stable COPD immunostained for identiﬁcation of (interleukin-37)+ cells
(arrows) in the bronchial submucosa. Results are representative of those from 11 non-smokers, 12 healthy smokers, 14 patients with mild/moderate
COPD and 18 patients with severe COPD. Bar=30 μm.
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online supplementary ﬁgure E6C), IL-18BPa (see online supple-
mentary ﬁgure E6D) and their IL-1β/ILRA (see online supple-
mentary ﬁgure E6E) and IL-18/IL-18BPa (see online
supplementary ﬁgure E6F) ratios and IL-37 between the two
group of subjects. Finally, BAL levels of IL-33 were under the
detection limit of the assay (data not shown) in all subjects (see
also online supplementary data repository).
Correlations between inﬂammatory cell counts,
IL-27-related molecules in the bronchi and clinical
parameters
Correlations restricted to patients with COPD alone show that
the number of IFNγRI+ cells correlated with the number of
IL-27+ (R=0.42, p=0.036) and IL-27R+ (R=0.51, p=0.014)
cells in the bronchial submucosa (ﬁgure 4A,B). The number of
IFNγRI+ cells also correlated with numbers of IL-7Rα (R=0.68,
p=0.0009). IL-7+ cell numbers correlated with the number of
IL-27+ (R=0.43, p=0.010) and IL-27R+ (R=0.51, p=0.003)
cells in the bronchial submucosa of patients with stable COPD
alone (ﬁgure 4C,D; see also online data supplement).
Inﬂammation and oxidative stress enhance IL-27 mRNA and
protein expression in NHBE cells in vitro, but not
inﬂammasome-related mRNAs
Stimulation of human bronchial epithelial cells in vitro with a
combination of oxidants (H2O2) and inﬂammatory cytokines
signiﬁcantly increased IL-27B mRNA and protein, but not the
inﬂammasome-related IL-1β, IL-18 and caspase 1 encoding
mRNAs (see online supplementary data repository and ﬁgures
E7, E8 and E9).
DISCUSSION
We show signiﬁcantly increased expression of IL-27 in the bron-
chial epithelium of patients with severe stable COPD compared
with smoking and non-smoking controls. In addition, the
number of IL-27+ and pSTAT1+ cells is also increased in the
bronchial submucosa of patients with severe stable COPD com-
pared with control smokers. This is associated with an increase
in the number of IL-27R+ cells in patients with severe stable
COPD compared with controls. Finally, in smokers, and in
patients with COPD, the number of IFNγRI+ cells correlated
with the number of IL-27+ and IL-27R+ cells. We failed to
show evidence for NRLP3 activation in the airways of patients
with stable COPD. Indeed, the levels of NRLP7 and IL-37, inhi-
bitors of NLRP3 activity, were upregulated in COPD.
We have previously reported increased pSTAT4 expression
linked to IFNγ expression21 but IL-27 can also induce IFNγ tran-
scription through a STAT1- and STAT3-mediated process.6 IL-27
also increases proliferation and IFNγ and granzyme B production
from human CD3-activated naïve CD8 cells. This results in
increased CD8+ T-cell-mediated cytotoxicity.22 IL-27 also drives
inducible regulatory T cells to produce IL-10.23 Although we
observed a signiﬁcant increase in the number of IL-10+ cells in
bronchial submucosa of patients with COPD and healthy
smokers, these numbers were very low in all subjects.
Furthermore, there was no difference in IL-10R expression in the
bronchial mucosa of patients with COPD. This, in conjunction
with the previous lack of changes in FoxP3+ regulatory T cells24
and low FoxP3 expressions in BAL T lymphocytes from patients
with stable COPD,25 suggests that a predominantly non-
regulatory CD25+ helper T-cell population is present in smokers
and patients with stable COPD. However, IL-10 expression is
reduced in the sputum of patients with stable COPD26 and add-
itional studies are required to clarify this discrepancy.
IL-27B mRNA and protein expression was upregulated in
normal primary human bronchial epithelial cells by combined
oxidative and pro-inﬂammatory stimuli. Although elevated
levels of IL-27 have been reported in COPD sputum27 there was
no increase in BAL IL-27 levels in patients with mild to severe
stable COPD in this study. This may reﬂect the different com-
partments sampled by BAL and by sputum28 or that IL-27 is
released from dead or dying sputum macrophages since we
show here that CD68 cells are the main source of IL-27.
IL-7+ cell numbers were increased in the bronchial mucosa
of stable COPD and control smokers compared with control
non-smokers despite no changes in BAL IL-7 being found. IL-7
Figure 3 Bronchoalveolar lavage
levels of (A) interleukin (IL)-6, (B)
IL-1RA, (C) HMGB1 and (D) soluble
ST2 in patients with stable COPD
(n=15) compared with control healthy
smokers (n=14). Results are expressed
as mean±SEM. Exact p values are
shown above each graph.
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is produced by stromal and epithelial cells whereas its receptor
is expressed mainly on T cells and monocytes.7 8 The increased
levels of IL-7, IL-7R and TSLPR observed here indicate that
IL-7 may have a local pro-inﬂammatory function increasing the
activation and survival of T cells and monocytes in the bronchial
submucosa of patients with severe stable COPD.29
IL-7+ cell numbers correlate with IL-27+ and IL-27R+ cells,
suggesting a functional relationship. The correlation between
numbers of IL-7Rα+ and INFγRI on one side, and the inverse
relationship between IL-7Rα and FEV1 % predicted on the
other, suggests a link between increased expression of this recep-
tor and increased severity in stable COPD. Overexpression of
IL-7Rα is linked to increased severity of inﬂammatory bowel
disease.8
High levels of IL-6 are released by sputum and BAL macro-
phages in vitro3 and IL-6 is increased in sputum of patients with
COPD during exacerbations.30 In our study, BAL levels of IL-6,
but not its soluble decoy receptor, were increased in COPD
despite no change in the numbers of IL-6+ and IL-6R+ cells.
Thus, our BAL data may simply reﬂect the presence of activated
macrophages in the peripheral airways of patients with stable
COPD. Soluble gp130 inhibits IL-6 trans-signalling via the
sIL-6R and classic signalling via the mIL-6R.31 In animal models,
sIL-6R-mediated signalling is an important intermediary in the
resolution of neutrophilic inﬂammation,31 but we were unable to
observe any signiﬁcant difference in the expression of sgp130 in
BAL from patients with stable COPD compared with control
smokers with normal lung function.
We report similar expression levels of NLRP3 in COPD and
control subjects, an absence of caspase-1 expression in patients
with COPD and controls, and no differences in the expression of
IL-1β, its receptors and IL-18 in COPD bronchial biopsies and in
the BAL level of IL-1β, IL-1RA, IL-18 and IL-18BPa, and their
IL-1β/IL-1RA and IL-18/IL-18BPa ratios in patients with stable
mild/moderate COPD versus control smokers with normal lung
function. This suggests that the NRLP3 inﬂammasome only
plays, at most, a minor role in the inﬂammatory response in the
central airways of stable COPD. The increased levels of IL-18Rβ
in bronchial biopsies of patients with severe COPD, compared
with patients with mild COPD and control smokers, reported
here, in the absence of a parallel increase in its own ligand, IL-18,
may have a limited biological function (table 3, ﬁgure 5).
We did not ﬁnd any difference in either IL-1β or IL-18
expression in the bronchial mucosa of patients with stable
COPD and control subjects in this study. This is in contrast to
increased levels of serum, sputum and BAL IL-1β,32–35 and
plasma and sputum IL-1836 37 reported in patients with COPD
compared with control smokers and non-smokers. Furthermore,
there is discordance between the levels of IL-18 and IL-1β in
patients with COPD, suggesting that coordinated induction
through the NRLP3 inﬂammasome is not critical for their
expression.36 38 Animal models of COPD also provide discord-
ant data on the role of the NLRP3 inﬂammasome.35 38 39
Original data38 suggested a role for IL-1β in smoke-induced
emphysema and airway remodelling but more recent data in
mice favour a role for inﬂammasome-independent induction of
IL-1β in driving smoke-induced inﬂammation.35 39 The expres-
sion of other inﬂammasome components in patients with stable
COPD has not been reported but the failure to detect increased
IL-1β and IL-18 expression in the bronchial mucosa and BAL in
this study suggests they may also play a limited role in patients
with stable COPD. However, NRLP3 inﬂammasome activation
may be important during viral and bacterial infections.11 13
Previous studies have shown elevated levels of IL-1β in exhaled
breath condensate and sputum during COPD exacerbations,
particularly when associated with bacterial infections.40
We observed a modest, albeit signiﬁcant, reduction of IL-1RA in
the BAL of patients with stable COPD compared with control
Figure 4 Regression analysis between numbers of (A) interferon (IFN)-γRI+ and interleukin (IL)-27+, (B) IFNγRI+ and IL-27R+, (C) IL-7+ and (D)
IL-27+, IL-7+ and IL-27R+ cells in the bronchial submucosa of all patients with COPD. Correlation coefﬁcients were calculated using the Spearman
rank method.
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smokers with normal lung function, which is in line with previ-
ous studies,41 but without signiﬁcant differences in their
IL-1β/IL-1RA ratio. This suggests that the BAL decrease of this
endogenous counter-regulatory mechanism of the IL-1β activa-
tion pathway may be clinically irrelevant. This is in line with
data from unpublished clinical trials showing that monoclonal
antibodies neutralising IL-1β signalling are ineffective in the
treatment of patients with stable COPD (http://clinicaltrials.gov/
ct2/show/results/NCT00581945).
Plasma and sputum HMGB1 levels have been previously
reported to be increased in patients with stable COPD com-
pared with control subjects42 but these studies were limited by
not having controls matched for age and smoking history. BAL
levels of HMGB1 have been reported as either increased in
patients with stable COPD41 or no different from controls.43 In
steroid-naïve patients with stable COPD, we found signiﬁcantly
decreased BAL HMGB1 levels, in comparison with age-matched
control smokers with normal lung function, although this differ-
ence was lost when outliers were removed, again suggesting a
minor role of inﬂammasome activation in the peripheral airways
or a role limited to a subset of COPD patients only.
Overexpression of human IL-37 in mice results in downregu-
lation of inﬂammation.17 The increased expression of IL-37
seen in the bronchial submucosa, but not in BAL, of patients
with stable COPD compared with control smokers suggests a
counter-regulatory role of this molecule. NALP7 attenuates
caspase-1-dependent IL-1β secretion by inhibiting the processing
of pro-IL-1β and pro-caspase 1.12 The increased expression of
NALP7 in the submucosa, but not BAL, of patients with stable
COPD may act to prevent the activation of the inﬂammasome
pathway (ﬁgure 5).
One limitation of this study is the failure to apply a
Bonferroni correction to the large number of biomarkers ana-
lysed. With Bonferroni correction the expression of IFNγRI,
NALP7, STAT1, IL27R and IL7Rα in the submucosa and of
NALP7 and TSLPR in the epithelium remain signiﬁcantly differ-
ent in patients with COPD, which supports the general message
reported here.
In summary, our results showing an increased expression of the
innate immunity cytokine IL-27 in the bronchial mucosa of
patients with stable COPD indicate its potential role in the
progression of severity of chronic bronchial inﬂammation. The
absence of NRLP3 inﬂammasome increase in patients with COPD
is associated with an increased expression of the inﬂammatory and
inﬂammasome inhibitory molecules IL-37 and NALP7. These data
suggest a relevant role for innate immunity and a silent state of
inﬂammasome activation in patients with stable COPD.
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Figure 5 Schematic representation of the molecular variations related to innate immunity (A) and inﬂammasome (B) in the bronchial biopsy
submucosa (values expressed as number of cells/mm2) of healthy non-smokers, healthy smokers, patients with mild/moderate stable COPD and
patients with severe/very severe stable COPD. *Signiﬁcantly different from healthy non-smokers; #signiﬁcantly different from healthy smokers. With
worsening of the disease, increased levels of interferon γ (IFNγ) are accompanied by increased levels of pSTAT1 and molecules inducing innate
immunity such as interleukin (IL)-27 and IL-7 (A). Molecules inducing activation of the inﬂammasome are not changed (NLRP3, caspase-1) and
IL-1β. Concomitantly, molecules inhibiting the inﬂammasome activation, such as IL-37 and NALP-7, are increased (B).
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